ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GSK Gsk Plc

1,705.40
0.20 (0.01%)
Last Updated: 13:50:13
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 0.01% 1,705.40 1,705.20 1,705.60 1,709.60 1,699.40 1,701.60 1,248,138 13:50:13
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.23 70.1B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,705.20p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £70.10 billion. Gsk has a price to earnings ratio (PE ratio) of 14.23.

Gsk Share Discussion Threads

Showing 18926 to 18948 of 33075 messages
Chat Pages: Latest  759  758  757  756  755  754  753  752  751  750  749  748  Older
DateSubjectAuthorDiscuss
24/1/2019
15:49
He's also behind top jobs for women
tradermichael
24/1/2019
15:19
sterling will keep appreciating, thank god, brexit unlikely to happen now even the biggest brexit morons understand the damage but that isnt why the share price perma chronic, its the over priced pharma buyout the market doesnt like, capital destructive, plus chairman going, hes been pretty hopeless as the share price has done nothing under new ceo but at least it was him who pushed for break up.
porsche1945
24/1/2019
14:08
1.20 to dollar? Maybe...but right now stg strengthening and GSK down.
zicopele
24/1/2019
12:29
All overseas earners in the FTSE seem to be getting hit, as investors think pound to get stronger. Market is sleep walking to the 29th March. Bad deal or no deal, pound going lower.
Shell, Gsk, Vod etc should bounce nicely as pound goes to 1.20 to the dollar.

montyhedge
24/1/2019
09:09
IN @ 1468.92 ……. ;0)
tradermichael
24/1/2019
07:49
Totally irrelevant, considering I hold GSK.
gbh2
23/1/2019
20:05
much better than aim stock
billionairepaddy
23/1/2019
19:57
Dire share price performance atm !
gbh2
23/1/2019
10:54
GlaxoSmithKline has a share of around 5% of the world's pharmaceutical market. The company employs around 99,300 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries. As of today, it has a market capitalisation of £73.5 billion, the seventh largest on the London Stock Exchange.

I'm staying put ….. at least till Emma's plan materialises ;0)

P.S. I buy large quantities and sell on the swings to regularly gain small increments. That, plus the dividends covers my needs - and I always re-invest the returns.

tradermichael
23/1/2019
09:49
When everything digested these will be higher, seems a crazy price.
montyhedge
23/1/2019
09:44
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (GBP4.0 billion). The transaction, which was announced on 3 December 2018, significantly strengthens GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology.

That's not good news TM! They already had crippling debt levels and this big transaction, being for cash, must worsen that. It was known for some time but the news of completion is nothing to celebrate, quite the reverse. :~(

What an appalling share GSK has been for long term growth investors. Glad I'm not one :~)

anhar
23/1/2019
09:02
£1 = US$1.30
tradermichael
22/1/2019
17:44
Nice and steady 👍
philanderer
22/1/2019
16:13
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (GBP4.0 billion). The transaction, which was announced on 3 December 2018, significantly strengthens GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology.

tradermichael
22/1/2019
13:05
Thanks all
watfordhornet
22/1/2019
12:57
Announcement date, Wednesday 6 February 2019.
Ex-dividend date*, Thursday 21 February 2019.
Record date, Friday 22 February 2019

Apparently.

wbecki
22/1/2019
12:57
2018 Q4 Ex-dividend date

Thursday 21 February 2019

tradermichael
22/1/2019
12:55
When does this go ex divi for next qtr payment. Apologies if obvious but cannot find the date
watfordhornet
22/1/2019
12:21
Can't get pass 1500p 1499p was the best so far.
montyhedge
22/1/2019
10:16
SP is very unstable.
abdullla
22/1/2019
08:55
1500p resistance point, but if break through and hold at close, that's a great pivotal point broken. Then onwards and upwards.
montyhedge
21/1/2019
15:29
RALLYYYYYYYYYY on this undiscovered stock ....
Futura Medical (FUM)= Market cap 20 million /Cash 10.5 million / Potency Drug with 2 BILLION Market potential close to Phase 3 readout /CSD500 Condom approved in Europe and many Countries outside of Europa + more Approvals & Licensing deals coming / TPR100 (Topical Gel for Pain ) first approval expected next Quarter = POTENTIAL 10++ BAGGER GEM

Futura Medical featured in Growth Company Investor recommendations 08 January 2019

CEO James Barder describes Futura as a medtech
rather than biotech business. Its proprietary technology is
DermaSys which delivers drugs rapidly through the skin and
into the blood system. The lead product is MED2005 which
is a topical gel for erectile dysfunction. The main advantage
over Viagra is that it takes effect within five minutes, compared
with over an hour for the famous blue pills. Which ensures key
ingredients of spontaneity and mood can be retained while
the treatment works. Research suggests a 20% market share
could be possible, equating to sales of $560m in major western
markets. In time an OTC version could more than double this.

bioking
21/1/2019
15:14
I agree with TM, but Porsche is correct in saying that this share price is very disappointing. We talk about £16 or more but it is proving very difficult to stay above £15 just now. I believe EW has a fresh outlook, which is exciting and adventurous, but as yet with no evidence to give us real confidence. But I am sticking with GSK for now.
jadeticl3
Chat Pages: Latest  759  758  757  756  755  754  753  752  751  750  749  748  Older

Your Recent History

Delayed Upgrade Clock